J. Driessen

First name
Middle name
H. M.
Last name
van Veelen, A., Abtahi, S., Souverein, P., Driessen, J. H. M., Klungel, O. H., Dingemans, A. C., et al. (2022). Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors. Cancer Epidemiol, 78, 102149. http://doi.org/10.1016/j.canep.2022.102149
Spaetgens, B., de Vries, F., Driessen, J. H. M., Leufkens, H. G., Souverein, P. C., Boonen, A., et al. (2017). Risk of infections in patients with gout: a population-based cohort study. Sci Rep. http://doi.org/10.1038/s41598-017-01588-5
Oshagbemi, O. A., Burden, A. M., Braeken, D. C. W., Henskens, Y., Wouters, E. F. M., Driessen, J. H. M., et al. (2017). Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. Am J Respir Crit Care Med. http://doi.org/10.1164/rccm.201701-0009LE
Oshagbemi, O. A., Keene, S. J., Driessen, J. H. M., Jordan, R., Wouters, E. F. M., de Boer, A., et al. (2018). Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 2013. Respir Med. http://doi.org/10.1016/j.rmed.2018.09.010
van Dalem, J., Brouwers, M., Stehouwer, C. D. A., Krings, A., Klungel, O. H., Driessen, J. H. M., et al. (2018). Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.13168
Simeonova, M., de Vries, F., Pouwels, S., Driessen, J. H. M., Leufkens, H. G. M., Cadarette, S. M., & Burden, A. M. (2018). Increased risk of all-cause mortality associated with domperidone use in Parkinson\textquoterights patients: a population-based cohort study in the UK. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.13708
Oshagbemi, O. A., Franssen, F. M. E., Wouters, E. F. M., van der Zee, A. H. M. -, Driessen, J. H. M., de Boer, A., & de Vries, F. (2019). C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD. Pulm Pharmacol Ther. http://doi.org/10.1016/j.pupt.2019.101870
Werkman, N. C. C., Nielen, J. T. H., van den Bergh, J. P. W., Ejskjaer, N., R\oikjer, J., Schaper, N. C., et al. (2020). Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation. Curr Drug Saf. http://doi.org/10.2174/1574886315666200805103053
Oshagbemi, O. A., Franssen, F. M. E., van Kraaij, S., Braeken, D. C. W., Wouters, E. F. M., van der Zee, A. H. M. -, et al. (2019). Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD). Copd. http://doi.org/10.1080/15412555.2019.1608172
de Bruin, I. J. A., Wyers, C. E., Souverein, P. C., van Staa, T. P., Geusens, P., van den Bergh, J. P. W., et al. (2020). The risk of new fragility fractures in patients with chronic kidney disease and hip fracture-a population-based cohort study in the UK. Osteoporos Int. http://doi.org/10.1007/s00198-020-05351-x